Bellicum Pharmaceuticals Inc (NASDAQ:BLCM) – Equities research analysts at Cantor Fitzgerald boosted their FY2018 earnings per share (EPS) estimates for Bellicum Pharmaceuticals in a research report issued to clients and investors on Wednesday. Cantor Fitzgerald analyst E. Piros now forecasts that the biopharmaceutical company will post earnings per share of ($2.74) for the year, up from their previous forecast of ($3.10). Cantor Fitzgerald currently has a “Buy” rating and a $10.00 target price on the stock.
A number of other research analysts have also recently commented on the company. Citigroup boosted their price target on Bellicum Pharmaceuticals from $24.00 to $27.00 and gave the stock a “hold” rating in a report on Friday, February 16th. ValuEngine cut Bellicum Pharmaceuticals from a “sell” rating to a “strong sell” rating in a report on Friday, February 2nd. SunTrust Banks lowered their price target on Bellicum Pharmaceuticals to $18.00 and set a “buy” rating on the stock in a report on Wednesday, January 31st. Wells Fargo cut Bellicum Pharmaceuticals from an “outperform” rating to a “market perform” rating and set a $6.00 price target on the stock. in a report on Wednesday, January 31st. Finally, Zacks Investment Research cut Bellicum Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Monday, January 22nd. Two equities research analysts have rated the stock with a sell rating, three have given a hold rating and five have given a buy rating to the company. The stock has a consensus rating of “Hold” and an average price target of $16.88.
Bellicum Pharmaceuticals stock opened at $7.96 on Monday. The company has a quick ratio of 6.08, a current ratio of 8.37 and a debt-to-equity ratio of 0.41. Bellicum Pharmaceuticals has a twelve month low of $5.02 and a twelve month high of $15.55. The company has a market capitalization of $267.23, a P/E ratio of -2.74 and a beta of 0.44.
In other Bellicum Pharmaceuticals news, major shareholder Bros. Advisors Lp Baker sold 880,735 shares of Bellicum Pharmaceuticals stock in a transaction that occurred on Friday, January 19th. The stock was sold at an average price of $8.20, for a total value of $7,222,027.00. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. In the last ninety days, insiders sold 1,141,822 shares of company stock worth $9,475,583. Corporate insiders own 18.77% of the company’s stock.
Large investors have recently added to or reduced their stakes in the business. Voya Investment Management LLC bought a new stake in Bellicum Pharmaceuticals in the 2nd quarter worth approximately $132,000. Commonwealth Equity Services Inc bought a new stake in Bellicum Pharmaceuticals in the 3rd quarter worth approximately $142,000. MYDA Advisors LLC bought a new stake in Bellicum Pharmaceuticals in the 4th quarter worth approximately $118,000. Cubist Systematic Strategies LLC bought a new stake in Bellicum Pharmaceuticals in the 3rd quarter worth approximately $164,000. Finally, Zurcher Kantonalbank Zurich Cantonalbank bought a new stake in Bellicum Pharmaceuticals in the 3rd quarter worth approximately $189,000. 55.14% of the stock is currently owned by institutional investors and hedge funds.
ILLEGAL ACTIVITY WARNING: This piece of content was posted by The Ledger Gazette and is owned by of The Ledger Gazette. If you are reading this piece of content on another site, it was illegally stolen and republished in violation of United States & international copyright and trademark laws. The legal version of this piece of content can be read at https://ledgergazette.com/2018/03/19/brokers-issue-forecasts-for-bellicum-pharmaceuticals-incs-fy2018-earnings-blcm.html.
Bellicum Pharmaceuticals Company Profile
Bellicum Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing cellular immunotherapies for various forms of cancer, including hematological cancers and solid tumors, as well as orphan inherited blood disorders. The Company uses its chemical induction of dimerization (CID) technology platform to engineer and then control components of the immune system.
Receive News & Ratings for Bellicum Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bellicum Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.